New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 24, 2014
06:30 EDTBCLIBrainStorm Cell granted U.S. patent for autologous stem cell technology
BrainStorm Cell Therapeutics announced that the U.S. Patent and Trademark Office has granted the company a key patent for its autologous stem cell technology. The patent covers BrainStorm's proprietary stem cells induced to secrete elevated levels of neurotrophic factors for the treatment of neurodegenerative diseases. The neurotrophic factors secreted by the company's patented cells include Glial Cell-Derived Neurotrophic Factor, or GDNF, and Brain-Derived Neurotrophic Factor, or BDNF, known to support the neural cell network by protection of existing motor neurons, promotion of motor neuron growth, and re-establishment of nerve-muscle interaction. The level of secretion of these factors is several-fold higher in BrainStorm's patented cells than in non-induced mesenchymal stem cells. Pending approval from the FDA, the company is currently preparing for its upcoming multi-center Phase II trial in the U.S. with its proprietary NurOwn stem cell therapy, which was developed with these cells.
News For BCLI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 16, 2014
08:58 EDTBCLIBrainStorm CEO underappreciated by investors, Feuerstein says
BrainStorm CEO Tony Fiorino is "one of the most honest and diligent investors in the health care sector," TheStreet's Adam Feuerstein writes after interviewing the executive. Feuerstein believes Fiorino is being underappreciated by investors. Shares of the microcap company seeking to development a treatment for amyotrophic lateral sclerosis are up 20% to $4.15 in pre-open trading. Reference Link
October 7, 2014
09:14 EDTBCLIOn The Fly: Pre-market Movers
Subscribe for More Information
07:11 EDTBCLIBrainStorm Cell's NurOwn designated as Fast Track product by FDA
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use